scholarly journals The Evolving Role of Catheter Ablation in Patients With Heart Failure and AF

2019 ◽  
Vol 8 (1) ◽  
pp. 47-53
Author(s):  
Sandeep Prabhu ◽  
Wei H Lim ◽  
Richard J Schilling
Keyword(s):  
Heart Failure ◽  
Clinical Practice ◽  
Catheter Ablation ◽  
Patient Group ◽  
Clinical Practice Guidelines ◽  
Practice Guidelines ◽  
Evidence Base ◽  
Patients With Heart Failure ◽  
Recent Developments

AF and heart failure are emerging epidemics worldwide. Several recent trials have provided a growing evidence base for the benefits of catheter ablation in this patient group, which are yet to be universally adopted in clinical practice guidelines. This paper provides a summary of recent developments in this field and provides pragmatic advice to the treating physician regarding the appropriate role of catheter ablation in the overall management of patients with comorbid AF and heart failure.

scholarly journals 2021 Clinical Practice Guidelines for Diabetes: Management of Cardiovascular Risk

2021 ◽  
Vol 22 (4) ◽  
pp. 259-267
Author(s):  
Min Kyong Moon
Keyword(s):  
Heart Failure ◽  
Clinical Practice ◽  
Cardiovascular Risk ◽  
Combination Therapy ◽  
Clinical Practice Guidelines ◽  
Practice Guidelines ◽  
Diabetes Management ◽  
Sglt2 Inhibitors ◽  
Atherosclerotic Cardiovascular Disease ◽  
Patients With Heart Failure

The Committee of Clinical Practice Guidelines of the Korean Diabetes Association revised and updated the 7th Clinical Practice Guidelines in 2021. Intense multifactorial intervention including adequate control of glycemia, blood pressure, and low density lipoprotein cholesterol level and use of antiplatelet agents has been shown to reduce cardiovascular risk among patients with type 2 diabetes mellitus. In these recent guidelines, sodium-glucose cotransporter-2 inhibitors (SGLT2 inhibitors) and glucagon-like peptide 1 receptor agonists (GLP-1 RAs) with proven benefits were recommended in patients with heart failure and/or atherosclerotic cardiovascular disease (ASCVD) as mono- or combination therapy. SGLT2 inhibitors such as dapagliflozin, empagliflozin, and ertugliflozin were recommended preferentially in patients with heart failure. In those with ASCVD, treatment including SGLT2 inhibitors such as empagliflozin and dapagliflozin or GLP-1 RAs such as dulaglutide, liraglutide, and semaglutide as a combination therapy was recommended.

THE ROLE OF EBM AND CLINICAL PRACTICE GUIDELINES IN GENERATING RESEARCH AND INTERVENTIONS IN NEGLECTED TROPICAL DISEASES: A RATIONAL MODEL FOR DEVELOPING COUNTRIES

2020 ◽  
Author(s):  
Cristhian David Morales-Plaza
Keyword(s):  
Developing Countries ◽  
Clinical Practice ◽  
Clinical Practice Guidelines ◽  
Practice Guidelines ◽  
Neglected Tropical Diseases ◽  
Tropical Diseases ◽  
Rational Model ◽  
Clinical Practices ◽  
Vulnerable Communities

Guarantee better clinical practices among clinicians who attend NTDs in developing countries as well as provide education in vector control in hotspot vulnerable communities

Sign in / Sign up

Export Citation Format

Share Document